Omeprazole is a drug of the proton pump inhibitor (PPI) class used to reduce stomach acid. It is prescribed for peptic ulcer disease, gastroesophageal reflux disease, erosive esophagitis, Zollinger–Ellison syndrome, and eradication of Helicobacter pylori infection. Introduced in 1988–1990, it was the first PPI in clinical practice and became one of the most widely dispensed medicines in the world. Chemically it is a substituted benzimidazole with the formula C₁₇H₁₉N₃O₃S, and it is sold as a racemic mixture of two enantiomers.
Chemistry and mechanism of action
Omeprazole is a weak base. The sulfur atom in its sulfinyl bridge is a stereogenic centre, which is why the molecule exists as two mirror-image forms. The drug is administered as an inactive precursor. It accumulates in the highly acidic compartment of the gastric parietal cell, where it is converted to a reactive sulfenamide species. This species forms covalent disulfide bonds with cysteine residues on the α-subunit of the H⁺/K⁺-ATPase, the enzyme that exports hydrogen ions into the stomach lumen in exchange for potassium. Because the enzyme is inactivated and must be resynthesized, acid output recovers only gradually after the drug is cleared.
Because the H⁺/K⁺-ATPase is the final step in hydrochloric acid production, omeprazole suppresses both basal and stimulated acid secretion, regardless of which stimulus (gastrin, histamine, or acetylcholine) triggers it. This distinguishes it from H₂-receptor antagonists such as cimetidine, which block only the histamine pathway. Acid inhibition begins within about an hour of an oral dose, with maximal effect around two hours. Because the effect outlasts the drug's plasma half-life, a single daily dose suppresses acid for much of the day. Since not all pumps are active at any moment, steady-state effects take several days to develop.
Omeprazole is metabolized mainly by the enzymes CYP2C19 and CYP3A4, which produce hydroxylated and sulfone metabolites. Genetic variation in CYP2C19 changes how quickly individuals clear the drug, and this is one reason for variable responses between patients.
Discovery and development
Research on acid suppression began in the 1960s, when several companies pursued different targets: gastrin release, gastrin receptors, histamine H₂ receptors, and the proton pump. The Swedish company Astra (later Astra Hässle) started its programme in 1966–1967. Early leads from a rival company, a class of benzimidazoles that were effective but toxic, were modified through a series of compounds that included timoprazole (1974) and picoprazole (1977). Omeprazole itself was identified in 1979. It was the first drug that acted directly on the proton pump in the parietal cell, a mechanism that was new at the time.
Omeprazole was launched in Sweden in 1988 under the name Losec. Its US market entry as Prilosec followed in 1990, although sources differ on the approval date, with one dating US approval to 1989. The drug quickly became Astra's best-selling product, and at its peak it was reported as the world's highest-selling drug. Its commercial success prompted the development of other PPIs, including lansoprazole, pantoprazole, and rabeprazole, all of which were introduced during the 1990s.
Clinical uses
Omeprazole is used for conditions in which reducing gastric acid is beneficial. Its approved and commonly used indications include:
- Duodenal and gastric ulcers, including ulcers associated with long-term use of nonsteroidal anti-inflammatory drugs
- Gastroesophageal reflux disease, including heartburn and regurgitation, and erosive esophagitis
- Zollinger–Ellison syndrome, a condition in which tumours produce excess gastrin and therefore large amounts of acid
- Dyspepsia and laryngopharyngeal reflux
- Eradication of H. pylori, usually as part of a combination regimen with two antibiotics such as clarithromycin and amoxicillin, or metronidazole for patients allergic to penicillin
In some countries omeprazole is available without a prescription for short-term symptom relief. In paediatric medicine, PPIs are licensed for children over one year of age for short-term treatment of GERD, healing of erosive esophagitis, peptic ulcer disease, and H. pylori eradication. Their use in very young children and infants is considered off-label in many settings.
Dosing and administration
The usual adult oral dose for acid-related disorders ranges from about 10 to 40 mg per day, with the exact amount depending on the condition and its severity. Omeprazole is generally given before a meal. Guidelines emphasise using the lowest effective dose for the shortest appropriate duration. Some clinical groups have proposed deprescribing or on-demand dosing for patients with uncomplicated reflux who have been symptom-free for a sustained period, and this remains an active area of clinical practice.
Adverse effects and safety
Short-term omeprazole use is generally well tolerated. Its most common adverse effects include headache, diarrhoea, abdominal pain, nausea, and dizziness. In controlled trials, the frequency of these effects was usually similar to that seen with placebo.
Long-term and high-dose use has been studied for several potential risks. Observational studies have reported associations with:
- Fractures of the hip, wrist, and spine, possibly related to reduced calcium absorption in the stomach
- Infections, including Clostridioides difficile enteric infection and community-acquired pneumonia; intensive-care use of PPIs as stress-ulcer prophylaxis has also been linked to higher rates of pneumonia
- Deficiencies of iron and vitamin B₁₂, although evidence for clinically important deficiency is limited
- Acute tubulointerstitial nephritis, an inflammation of the kidney that is a rare idiosyncratic reaction and has been reported since the introduction of PPIs
- Fundic gland polyps in the stomach, which are generally benign
Causal interpretation of many observational findings remains debated, because patients taking PPIs may differ in other ways from those who do not. Regulatory agencies have issued labelling updates on several of these topics, and the balance of benefit and risk varies by indication.
Drug interactions
Omeprazole inhibits CYP2C19 and CYP2C9 and can increase blood levels of drugs that these enzymes metabolize, including diazepam, escitalopram, and warfarin. Its interaction with clopidogrel, an antiplatelet prodrug, has received particular attention. Clopidogrel requires CYP2C19 for activation, so omeprazole may reduce its antiplatelet effect. Regulators have advised against combining the two in many cases, since reduced clopidogrel activity may raise the risk of stroke and cardiovascular events. Omeprazole also inhibits the efflux transporter P-glycoprotein, and as an acid suppressant it can alter the absorption of drugs whose uptake depends on gastric pH.
Esomeprazole and the chiral switch
Esomeprazole is the (S)-enantiomer of omeprazole. Astra developed it as a second-generation product and launched it around 2000 under the brand name Nexium. Its marketing rested on the claim that a single enantiomer gives more consistent metabolism and somewhat greater acid suppression per dose. Esomeprazole became one of the best-known examples of a chiral switch, in which an established racemic drug is replaced by one of its enantiomers. Whether the single-enantiomer form offers meaningful clinical advantages over racemic omeprazole has been debated, and in many markets esomeprazole and omeprazole have been priced and promoted in competition with each other.
Significance and debates
Omeprazole changed the management of acid-related disease. Peptic ulcer disease, which had often required surgery or long courses of H₂ antagonists, became far more treatable. The discovery of the H. pylori link to ulcers, which was recognised by researchers in the 1980s, further increased the importance of PPIs in combination therapy.
Several questions remain under active study. These include the long-term safety of continuous PPI use, the appropriate duration of treatment, the role of PPIs in older adults, and the reasons for the rapid growth in use in many countries, including use that may exceed clinical indications. Discussion of these issues appears in clinical guidelines and in health-system reviews of prescribing patterns.
References
- Omeprazole: Uses, Interactions, Mechanism of Actiongo.drugbank.com
- Omeprazole - StatPearls - NCBI Bookshelf - NIHncbi.nlm.nih.gov
- Omeprazole - an overviewsciencedirect.com
- A Narrative Review on Efficacy and Safety of Proton Pump Inhibitors in Childrenncbi.nlm.nih.gov
- Compositions and methods for delivery of omeprazole plus acetylsalicylic acidimage-ppubs.uspto.gov
- Compositions and methods for delivery of omeprazole plus acetylsalicylic acidimage-ppubs.uspto.gov
- What is the mechanism of Omeprazole?synapse.patsnap.com
- Methods for treating helicobacter pylori infectionimage-ppubs.uspto.gov
- 132fb14.uni-frankfurt.de
- THE PHARMACEUTICAL JOURNAL VOL 296 NO 7890 JUNE 2016pharmaceutical-journal.com
- IOS Press Ebooks - The Omeprazole Story: How Endurance in Research May Pay Offebooks.iospress.nl
- Omeprazole - an overviewsciencedirect.com
- Process for the preparation of esomeprazole and salts thereofimage-ppubs.uspto.gov
- Process for the preparation of esomeprazole and salts thereofimage-ppubs.uspto.gov
- Esomeprazolechiralpedia.com
- Amorphous esomeprazole hydrateimage-ppubs.uspto.gov
- Amorphous hydrous esomeprazole magnesiumimage-ppubs.uspto.gov